Schistosomiasis: From drug deployment to drug development

Current Opinion in Infectious Diseases

Volumn 24, Issue 5, 2011, Pages 410-417

  Caffrey, Conor R ^a   Secor, W Evan ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

anthelmintic; praziquantel; schistosomiasis; TRND; tropical disease; WHO TDR

Indexed keywords

DNA; MEFLOQUINE; OXADIAZOLE DERIVATIVE; PRAZIQUANTEL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RNA;

DRUG DISTRIBUTION; DRUG EFFICACY; DRUG REPOSITIONING; DRUG RESISTANCE; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL GENOMICS; GENOME; HUMAN; MEDICAL DOCUMENTATION; NONHUMAN; PHENOTYPE; REVIEW; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMA JAPONICUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SINGLE DRUG DOSE;

ANTHELMINTICS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE; HUMANS; PRAZIQUANTEL; SCHISTOSOMIASIS; SCHISTOSOMICIDES;

EID: 80052483092     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328349156f     Document Type: Review

References (87)

1. King CH. Parasites and poverty: the case of schistosomiasis. Acta Trop 2010; 113:95-104.
2. Utzinger J, N'Goran EK, Caffrey CR, Keiser J. From innovation to application: social-ecological context, diagnostics, drugs and integrated control of schistosomiasis. Acta Trop 2010 [Epub ahead of print]. doi:10.1016/j.actratropica. 2010.08.020
3. Molyneux DH. Combating the 'other diseases' of MDG 6: changing the paradigm to achieve equity and poverty reduction? Trans R Soc Trop Med Hyg 2008; 102:509-519.
4. Molyneux DH, Hotez PJ, Fenwick A. Rapid-impact interventions: how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med 2005; 2:e336.
5. Steinmann P, Keiser J, Bos R, et al. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006; 6:411-425. (Pubitemid 43949139)
6. Doenhoff MJ, Hagan P, Cioli D, et al. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology 2009; 136:1825-1835.
7. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 2006; 368:1106-1118. (Pubitemid 44402679)
8. Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through control of neglected tropical diseases. Lancet 2009; 373:1570-1575.
9. Smits HL. Prospects for the control of neglected tropical diseases by mass drug administration. Exp Rev Antiinfect Ther 2009; 7:37-56.
10. Abdul-Ghani RA, Loutfy N, Hassan A. Experimentally promising antischistosomal drugs: a review of some drug candidates not reaching the clinical use. Parasitol Res 2009; 105:899-906.
11. Geary TG, Woo K, McCarthy JS, et al. Unresolved issues in anthelmintic pharmacology for helminthiases of humans. Int J Parasitol 2010; 40:1-13.
12. World Health Organization. Prevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert committee. In: World Health Organ Tech Rep Ser. World Health Organization; 2002. Vol. 912.
13. Black CL, Steinauer ML, Mwinzi PN, et al. Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya. Trop Med Int Health 2009; 14:450-457.
14. Botros S, Sayed H, Amer N, et al. Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt. Int J Parasitol 2005; 35:787-791. (Pubitemid 40733617)
15. Guidi A, Andolina C, Makame Ame S, et al. Praziquantel efficacy and longterm appraisal of schistosomiasis control in Pemba Island. Trop Med Int Health 2010; 15:614-618.
16. Wang W, Dai JR, Li HJ, et al. Is there reduced susceptibility to praziquantel in Schistosoma japonicum? Evidence from China. Parasitology 2010; 137: 1905-1912.
17. Webster JP, Gower CM, Norton AJ. Evolutionary concepts in predicting and evaluating the impact of mass chemotherapy schistosomiasis control programmes on parasites and their hosts. Evol Appl 2008; 1:66-83.
18. Gurarie D, Wang X, Bustinduy AL, King CH. Modeling the effect of chronic schistosomiasis on childhood development and the potential for catch-up growth with different drug treatment strategies promoted for control of endemic schistosomiasis. Am J Trop Med Hyg 2011; 84:773-781.
19. Fenwick A, Webster JP, Bosque-Oliva E, et al. The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002-2008. Parasitology 2009; 136:1719-1730.
20. Brindley PJ, Sher A. The chemotherapeutic effect of praziquantel against Schistosoma mansoni is dependent on host antibody response. J Immunol 1987; 139:215-220. (Pubitemid 17091787)
21. Sabah AA, Fletcher C, Webbe G, Doenhoff MJ. Schistosoma mansoni: reduced efficacy of chemotherapy in infected T-cell-deprived mice. Exp Parasitol 1985; 60:348-354. (Pubitemid 16178911)
22. Shaw MK. Schistosoma mansoni: stage-dependent damage after in vivo treatment with praziquantel. Parasitology 1990; 100 (Pt 1):65-72. (Pubitemid 20120799)
23. Sabah AA, Fletcher C, Webbe G, Doenhoff MJ. Schistosoma mansoni: chemotherapy of infections of different ages. Exp Parasitol 1986; 61: 294-303. (Pubitemid 16069841)
24. Xiao SH, Yue WJ, Yang YQ, You JQ. Susceptibility of Schistosoma japonicum to different developmental stages to praziquantel. Chin Med J (Engl) 1987; 100:759-768.
25. Gryseels B, Mbaye A, De Vlas SJ, et al. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop Med Int Health 2001; 6:864-873. (Pubitemid 33010872)
26. Clerinx J, Van Gompel A. Schistosomiasis in travellers and migrants. Travel Med Infect Dis 2011; 9:6-24.
27. Helleberg M, Thybo S. High rate of failure in treatment of imported schistosomiasis. J Travel Med 2010; 17:94-99.
28. Lamberton PH, Hogan SC, Kabatereine NB, et al. In vitro praziquantel test capable of detecting reduced in vivo efficacy in Schistosoma mansoni human infections. Am J Trop Med Hyg 2010; 83:1340-1347.
29. Norton AJ, Gower CM, Lamberton PH, et al. Genetic consequences of mass human chemotherapy for Schistosoma mansoni: population structure pre and postpraziquantel treatment in Tanzania. Am J Trop Med Hyg 2010; 83:951-957.
30. Pax R, Bennett JL, Fetterer R. A benzodiazepine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum. Naunyn Schmiedebergs Arch Pharmacol 1978; 304:309-315. (Pubitemid 9060920)
31. Fetterer RH, Pax RA, Bennett JL. Praziquantel, potassium and 2,4-dinitrophenol: analysis of their action on the musculature of Schistosoma mansoni. Eur J Pharmacol 1980; 64:31-38. (Pubitemid 10123935)
32. Becker B, Mehlhorn H, Andrews P, et al. Light and electron microscopic studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro. Z Parasitenkd 1980; 63:113-128. (Pubitemid 11252325)
33. Gnanasekar M, Salunkhe AM, Mallia AK, et al. Praziquantel affects the regulatory myosin light chain of Schistosoma mansoni. Antimicrob Agents Chemother 2009; 53:1054-1060.
34. Jeziorski MC, Greenberg RM. Voltage-gated calcium channel subunits from platyhelminths: potential role in praziquantel action. Int J Parasitol 2006; 36:625-632. (Pubitemid 43765718)
35. Angelucci F, Basso A, Bellelli A, et al. The antischistosomal drug praziquantel is an adenosine antagonist. Parasitology 2007; 134:1215-1221. (Pubitemid 47174071)
36. Kasinathan RS, Goronga T, Messerli SM, et al. Modulation of a Schistosoma mansoni multidrug transporter by the antischistosomal drug praziquantel. FASEB J 2011; 24:128-135.
37. Kasinathan RS, Greenberg RM. Pharmacology and potential physiological significance of schistosome multidrug resistance transporters. Exp Parasitol 2011. [Epub ahead of print]. doi:10.1016/j.exppara.2011.03.004
38. Kasinathan RS, Morgan WM, Greenberg RM. Schistosoma mansoni express higher levels of multidrug resistance-associated protein 1 (SmMRP1) in juvenile worms and in response to praziquantel. Mol Biochem Parasitol 2010; 173:25-31.
39. Aragon AD, Imani RA, Blackburn VR, et al. Towards an understanding of the mechanismof action of praziquantel. Mol BiochemParasitol 2009; 164:57-65.
40. Geary TG, Woods DJ, Williams T, Nwaka S. Target identification and mechanism-based screening for anthelmintics: application of veterinary antiparasitic research programs to search for new antiparasitic drugs for human indications. In: Selzer PM, editor. Antiparasitic and antibacterial drug discovery. Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany. 2009. pp. 3-15.
41. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008; 4:682-690.
42. Frearson JA, Wyatt PG, Gilbert IH, Fairlamb AH. Target assessment for antiparasitic drug discovery. Trends Parasitol 2007; 23:589-595. (Pubitemid 350161429)
43. Andrews P, Thomas H, Pohlke R, Seubert J. Praziquantel.Med Res Rev 1983; 3:147-200. (Pubitemid 13059325)
44. Harder A. Milestones of helmintic research at Bayer. Parasitol Res 2002; 88:477-480. (Pubitemid 34328099)
45. Keiser J. In vitro and in vivo trematode models for chemotherapeutic studies. Parasitology 2009; 137:589-603.
46. Drug development and evaluation for helminths and other neglected tropical diseases. Geneva: TDR/World Health Organization; 2010. p. 46.
47. Abdulla MH, Ruelas DS, Wolff B, et al. Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by mediumthroughput phenotypic screening. PLoS Negl Trop Dis 2009; 3:e478.
48. Ramirez B, Bickle Q, Yousif F, et al. Schistosomes: challenges in compound screening. Exp Opin Drug Discov 2007; 2:S53-S61. (Pubitemid 47616030)
49. Sayed AA, Simeonov A, Thomas CJ, et al. Identification of oxadiazoles as newdrug leads for the control of schistosomiasis. NatMed 2008; 14:407-412. (Pubitemid 351499390)
50. Kuntz AN, Davioud-Charvet E, Sayed AA, et al. Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med 2007; 4:e206.
51. Simeonov A, Jadhav A, Sayed AA, et al. Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade. PLoS Negl Trop Dis 2008; 2:e127.
52. Rai G, Sayed AA, Lea WA, et al. Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis. J Med Chem 2009; 52:6474-6483.
53. Keiser J, Utzinger J. Artemisinins and synthetic trioxolanes in the treatment of helminth infections. Curr Opin Infect Dis 2007; 20:605-612. (Pubitemid 350059520)
54. Sissoko MS, Dabo A, Traore H, et al. Efficacy of artesunate sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children. PLoS One 2009; 4:e6732.
55. Midzi N, Sangweme D, Zinyowera S, et al. The burden of polyparasitism among primary schoolchildren in rural and farming areas in Zimbabwe. Trans R Soc Trop Med Hyg 2008; 102:1039-1045.
56. Wilson S, Vennervald BJ, Kadzo H, et al. Health implications of chronic hepatosplenomegaly in Kenyan school-aged children chronically exposed to malarial infections and Schistosoma mansoni. Trans R Soc Trop Med Hyg 2010; 104:110-116.
57. Keiser J, Chollet J, Xiao SH, et al. Mefloquine: an aminoalcohol with promising antischistosomal properties in mice. PLoS Negl Trop Dis 2009; 3:e350.
58. Holtfreter MC, Loebermann M, Klammt S, et al. Schistosoma mansoni: schistosomicidal effect of mefloquine and primaquine in vitro. Exp Parasitol 2011; 127:270-276.
59. Xiao SH, Mei JY, Jiao PY. Effect of mefloquine administered orally at single, multiple, or combined with artemether, artesunate, or praziquantel in treatment of mice infected with Schistosoma japonicum. Parasitol Res 2011; 108:399-406.
60. Van Nassauw L, Toovey S, Van Op den Bosch J, et al. Schistosomicidal activity of the antimalarial drug, mefloquine, in Schistosoma mansoni-infected mice. Travel Med Infect Dis 2008; 6:253-258.
61. Keiser J, N'Guessan NA, Adoubryn KD, et al. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial. Clin Infect Dis 2010; 50:1205-1213.
62. Eissa MM, El-Azzouni MZ, Amer EI, Baddour NM. Miltefosine, a promising novel agent for schistosomiasis mansoni. Int J Parasitol 2011; 41:235-242.
63. Niederlein A, Meyenhofer F, White D, Bickle M. Image analysis in high-content screening. Comb Chem High Throughput Screen 2009; 12:899-907.
64. Green RA, Kao HL, Audhya A, et al. A high-resolution C. elegans essential gene network based on phenotypic profiling of a complex tissue. Cell 2011; 145:470-482.
65. Manneck T, Braissant O, Haggenmuller Y, Keiser J. Isothermal microcalorimetry to study drugs against Schistosoma mansoni. J Clin Microbiol 2011; 49:1217-1225.
66. Smout MJ, Kotze AC, McCarthy JS, Loukas A. A novel high throughput assay for anthelmintic drug screening and resistance diagnosis by real-time monitoring of parasite motility. PLoS Negl Trop Dis 2010; 4:e885.
67. Holtfreter MC, Loebermann M, Frei E, et al. Schistosomula, preadults and adults of Schistosoma mansoni ingest fluorescence-labelled albumin in vitro and in vivo: implication for a drug-targeting model. Parasitology 2010; 137:1645-1652.
68. Peak E, Chalmers IW, Hoffmann KF. Development and validation of a quantitative, high-throughput, fluorescent-based bioassay to detect Schistosoma viability. PLoS Negl Trop Dis 2010; 4:e759.
69. Mansour NR, Bickle QD. Comparison of microscopy and Alamar blue reduction in a larval based assay for schistosome drug screening. PLoS Negl Trop Dis 2010; 4:e795.
70. Singh R, Pittas MI, Heskia I, et al. Automated image-based phenotypic screening for high-throughput drug discovery. In: Proceedings of 22nd IEEE Symposium on Computer-Based Medical Systems, 2009; Albuquerque, New Mexico, USA.
71. Berriman M, Haas BJ, LoVerde PT, et al. The genome of the blood fluke Schistosoma mansoni. Nature 2009; 460:352-358.
72. Tsai I, Otto TD, Berriman M. Improving draft assemblies by iterative mapping and assembly of short reads to eliminate gaps. Genome Biol 2010; 11:R41.
73. Schistosoma japonicum Genome Sequencing and Functional Analysis Consortium. The Schistosoma japonicum genome reveals features of host-parasite interplay. Nature 2009; 460:345-351.
74. Stefanic S, Dvorak J, Horn M, et al. RNA interference in Schistosoma mansoni schistosomula: selectivity, sensitivity and operation for larger-scale screening. PLoS Negl Trop Dis 2010; 4:e850.
75. Garba A, Barkire N, Djibo A, et al. Schistosomiasis in infants and preschoolaged children: Infection in a single Schistosoma haematobium and a mixed S. haematobium-S. mansoni foci of Niger. Acta Trop 2010; 115:212-219.
76. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002; 1:727-730. (Pubitemid 37361545)
77. Fitzpatrick JM, Peak E, Perally S, et al. Antischistosomal intervention targets identified by lifecycle transcriptomic analyses. PLoS Negl Trop Dis 2009; 3:e543.
78. Dissous C, Grevelding CG. Piggy-backing the concept of cancer drugs for schistosomiasis treatment: a tangible perspective? Trends Parasitol 2010; 27:59-66.
79. Andrade LF, Nahum LA, Avelar LGA, et al. Eukaryotic protein kinases (ePKs) of the Helminth Parasite Schistosoma mansoni. BMC Genomics 2011; 12:215.
80. Abdulla MH, Lim KC, Sajid M, et al. Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Med 2007; 4:e14.
81. Bos DH, Mayfield C, Minchella DJ. Analysis of regulatory protease sequences identified through bioinformatic data mining of the Schistosoma mansoni genome. BMC Genomics 2009; 10:488.
82. Caffrey CR, Rohwer A, Oellien F, et al. A comparative chemogenomics strategy to predict potential drug targets in the metazoan pathogen, Schistosoma mansoni. PLoS One 2009; 4:e4413.
83. Crowther GJ, Shanmugam D, Carmona SJ, et al. Identification of attractive drug targets in neglected-disease pathogens using an in silico approach. PLoS Negl Trop Dis 2010; 4:e804.
84. Aguero F, Al-Lazikani B, Aslett M, et al. Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov 2008; 7:900-907.
85. Swierczewski BE, Davies SJ. A schistosome cAMP-dependent protein kinase catalytic subunit Is essential for parasite viability. PLoS Negl Trop Dis 2009; 3:e505.
86. Tchoubrieva EB, Ong PC, Pike RN, et al. Vector-based RNA interference of cathepsin B1 in Schistosoma mansoni. Cell Mol Life Sci 2010; 67:3739-3748.
87. Rinaldi G, Suttiprapa S, Brindley PJ. Quantitative retrotransposon anchored PCR confirms transduction efficiency of transgenes in adult Schistosoma mansoni. Mol Biochem Parasitol 2011; 177:70-76.